Legend Biotech Corp (LEGN) Stock

Legend Biotech Corporation develops, manufactures, and commercializes chimeric antigen receptor T-cell (CAR-T) therapies for oncology and other serious diseases. The company's flagship product is CARVYKTI, a BCMA-targeted CAR-T cell therapy for relapsed or refractory multiple myeloma, developed and marketed through a collaboration with Janssen, a Johnson & Johnson subsidiary. As a clinical and commercial-stage biopharmaceutical company, Legend Biotech operates an integrated end-to-end cell therapy model encompassing research, development, manufacturing, and commercialization across the United States, China, and Europe. The company maintains a diversified pipeline including investigational autologous CAR-T candidates targeting various hematologic malignancies and solid tumors, such as non-Hodgkin lymphoma, small cell lung cancer, and gastric cancer, alongside allogeneic gamma delta CAR-T and CAR-NK platform technologies. With major manufacturing facilities including the largest cell therapy manufacturing facility in the United States located in Raritan, New Jersey, and a production facility in Ghent, Belgium, Legend Biotech generates revenue primarily through license and collaboration agreements. Founded in 2014 and headquartered in Somerset, New Jersey, the company positions itself as the largest standalone cell therapy company focused on transforming cancer treatment through personalized immunotherapy approaches.